Technology

OBI has developed a unique glycan ADC platform (GlycOBI^®), which are in a ‘Plug and Play’ format and compatible with any antibodies, linkers, and payloads in various Drug antibody ratio (DAR). Utilizing OBI’s proprietary enzymatic technology (EndoSymeOBI^®) and novel linker-payload technology, GlycOBI^® generates site-specific homogenous ADCs with an efficient and scalable process. The conjugation process of GlycOBI^® avoids disrupting the antibody structure and ensures the ADC has similar biophysical characteristics to the native antibody. Furthermore, OBI’s linker technology has improved conjugation efficiency of the payload and reduced aggregation propensity, and also expanded the half-life of the ADC products. GlycOBI^® has overcome the limitations of traditional ADCs and achieved better efficacy and stability in various in vivo tests.

GlycOBI DUO™ Technology is an advanced site-specific conjugation platform developed by OBI to enable the next generation of antibody-drug conjugates (ADCs). Built on the precision of glycan engineering, this platform allows for the controlled and modular installation of two distinct cytotoxic payloads, each with a different mechanism of action (MOA), in a flexible and tunable ratio.

By leveraging the unique architecture of the GlycOBI^® system, this dual-payload approach addresses key limitations of traditional ADCs. The ability to combine complementary MOAs enhances antitumor potency and broadens therapeutic coverage, allowing ADCs to more effectively tackle tumor heterogeneity. Additionally, the strategic pairing of payloads offers a potential strategy to overcome drug resistance mechanisms, providing sustained efficacy even in challenging tumor . GlycOBI DUO™ incorporates GlycOBI^® and HYPrOBI™ technologies to enable the generation of dual-payload ADCs without introducing potential aggregation liabilities.

This technology not only boosts the overall activity of ADCs but also opens the door to tailored therapeutic designs, making it a powerful engine for the development of next-generation cancer therapeutics with improved specificity, durability, and clinical potential.

The ThiOBI^® platform represents a cutting-edge approach for the development of next-generation cysteine (Cys)-based drug conjugates, supporting a wide range of cysteine-containing biomolecules, such as nanobodies, antibody fragments, and peptides. Built upon OBI’s proprietary HYPrOBI™ linker technology, ThiOBI^® utilizes a novel hydrophilic and stable linker that enhances solubility, prolongs circulation stability, and ensures efficient drug release at the tumor site. Additionally, its irreversible thiol conjugation chemistry enables precise and selective modification of Cys residues, offering meticulous control over the conjugation process and consistent product quality. The technology also supports dual-payload ADC designs without inducing aggregation, offering expanded flexibility for complex therapeutic strategies. ThiOBI^® will be presented at AACR 2025, showcasing its conjugation strategy and promising preclinical data.

EndoSymeOBI^® is our pioneer enzyme technology which allows antibody glycan modification within a single step, including removing multiple types of sugar molecules and linking specially designed sugar molecules or their derivatives to the antibody. Giving the needs of drug development, EndoSymeOBI^® processed antibody retain its stability and binding activity without altering disulfide bonds. The EndoSymeOBI^® platform excels in diverse applications from sugar molecule removal to site-specific antibody-drug conjugate (ADC) production, and antibody homogenization. EndoSymeOBI^® directly enhances the functionality of antibodies, offering more effective solutions for developing therapeutics for cancer, immune system diseases and others.

HYPrOBI™ is an OBI’s proprietary linker technology, specifically engineered to enhance the overall stability, efficacy, and pharmacological performance of ADCs. This innovative technology integrates two critical features: the “masking” and the “shielding” effects.

The masking effect incorporates hydrophilic moieties into the linker structure to effectively mask the hydrophobicity of the payload. This design reduces the propensity for aggregation, improves solubility, and allows greater flexibility in achieving higher drug-to-antibody ratios (DARs) without compromising ADC stability.

The shielding effect introduces a strategic steric hindrance around the payload, preventing premature drug release in circulation. This ensures that the payload remains stable and is selectively at the tumor site. The result is a controlled, slow-release profile that supports expanded and durable anti-tumor activity.